1 results match your criteria: "Germany kUT Southwestern Medical Center[Affiliation]"
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
AIDS
March 2015
aIcahn School of Medicine at Mount Sinai, New York, USA bChelsea and Westminster Hospital, London, UK cHospital Carlos III, Madrid, Spain dEPIMED, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany eHospital de la Santa Creu i Sant Pau, Barcelona, Spain fUniversity of Bonn, Bonn, Germany gRoyal Free Hospital, London, UK hHospital Clínic iHospital Universitari Germans Trias i Pujol and Universitat Autònoma de Barcelona, Barcelona, Spain jMedizinisches Infektiologiezentrum Berlin (MIB), Berlin, Germany kUT Southwestern Medical Center, Dallas, Texas lBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA mBoehringer Ingelheim España S.A., Barcelona, Spain.
Objective: Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. STARTVerso4 assessed the efficacy and safety of faldaprevir and response-guided pegylated interferon α-2a/ribavirin (PegIFN/RBV) in individuals with HCV/HIV co-infection.
Design: A phase 3 open-label study (NCT01399619).